- Home
- OBIO vs ENTX Comparison
OBIO vs ENTX Comparison
Compare OBIO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- ENTX
- Stock Information
- Founded
- OBIO 2017
- ENTX 2010
- Country
- OBIO United States
- ENTX Israel
- Employees
- OBIO N/A
- ENTX N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OBIO Health Care
- ENTX Health Care
- Exchange
- OBIO Nasdaq
- ENTX Nasdaq
- Market Cap
- OBIO 124.9M
- ENTX 104.0M
- IPO Year
- OBIO N/A
- ENTX 2018
- Fundamental
- Price
- OBIO $3.01
- ENTX $1.98
- Analyst Decision
- OBIO Strong Buy
- ENTX Strong Buy
- Analyst Count
- OBIO 5
- ENTX 1
- Target Price
- OBIO $14.20
- ENTX $10.00
- AVG Volume (30 Days)
- OBIO 236.8K
- ENTX 42.8K
- Earning Date
- OBIO 08-11-2025
- ENTX 08-08-2025
- Dividend Yield
- OBIO N/A
- ENTX N/A
- EPS Growth
- OBIO N/A
- ENTX N/A
- EPS
- OBIO N/A
- ENTX N/A
- Revenue
- OBIO $2,886,000.00
- ENTX $223,000.00
- Revenue This Year
- OBIO $20.47
- ENTX N/A
- Revenue Next Year
- OBIO $11.45
- ENTX N/A
- P/E Ratio
- OBIO N/A
- ENTX N/A
- Revenue Growth
- OBIO 30.23
- ENTX N/A
- 52 Week Low
- OBIO $2.37
- ENTX $1.41
- 52 Week High
- OBIO $8.87
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- OBIO 47.82
- ENTX 48.00
- Support Level
- OBIO $2.91
- ENTX $1.87
- Resistance Level
- OBIO $3.48
- ENTX $2.18
- Average True Range (ATR)
- OBIO 0.26
- ENTX 0.18
- MACD
- OBIO -0.01
- ENTX -0.00
- Stochastic Oscillator
- OBIO 28.78
- ENTX 31.82
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.